ABSTRACT
A significant number of cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by establishing a highly dysfunctional state in T-cells. To identify shared features associated to PD- 1/LAG-3 dysfunctionality in human cancers and T-cells, multiomic expression profiles were obtained for all TCGA cancers with high T-cell infiltration. A PD-1/LAG-3 dysfunctional signature was found which regulated immune, metabolic, genetic and epigenetic pathways. These results were validated in T-cell lines with constitutively active PD-1, LAG-3 pathways and their combination. These results uncovered distinct degrees of T-cell dysfunctionality. Global changes were cross-evaluated among T- cell lines with multiomic biopsy data to identify genetic, metabolic, and proteomic programmes regulated by PD-1/LAG-3 dysfunctionality. One of these relied on differential regulation of E3 ubiquitin ligases CBL-B and C-CBL. PD-1/LAG-3 co-blockade with a bispecific drug under clinical development but not with a combination of anti-PD-1/anti-LAG-3 antibodies achieved both CBL-B and C-CBL inhibition, reverting T-cell dysfunctionality in lung cancer patients resistant to PD-L1/PD- 1 blockade.
Competing Interest Statement
C.J.E, J.L. and D.E. are inventors of the Humabody CB213 (WO/2019/158942. Crescendo Biologics Ltd.). The rest of the authors declare no conflicts of interest.
Funding Statement
This research was supported by The Spanish Association against Cancer, Instituto de Salud Carlos III (ISCIII)_FEDER, Department of Health of the Government of Navarre_FEDER, Strategic projects from the Department of Industry, Government of Navarre; European Union Horizon 2020 ISOLDA project, under grant agreement ID 848166.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The prospective observational study was approved by the Ethics Committee of Clinical Investigations at the University Hospital of Navarre (reference number: PI_2020/115). Informed consent was obtained from all subjects, and all experiments conformed to the principles in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report. Clinical details and composition of the cohort under study are described elsewhere (Arasanz et al., 2020; Bocanegra et al., 2022; Zuazo et al., 2019).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Mass-spectrometry data and search results files were deposited in the Proteome Xchange Consortium via the JPOST partner repository (https://repository.jpostdb.org; Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210561/) with the identifier PXD040408 for ProteomeXchange and JPST002062 for jPOST (for reviewers: https://repository.jpostdb.org/preview/118930299263fc6310a6249; Access key: 7060).
https://repository.jpostdb.org/preview/118930299263fc6310a6249
KEY ABRREVIATIONS
- • PD-1
- “Programmed cell death protein 1” protein.
- • LAG-3
- “Lymphocyte-activation gene 3” protein.
- • PDCD1 or PD1
- “Programmed cell death protein 1” gene.
- • LAG3
- “Lymphocyte-activation gene 3” gene.
- • CTLA4
- “Cytotoxic T-Lymphocyte Antigen 4” gene.
- • TIM3 or HAVCR2
- “Hepatitis A Virus Cellular Receptor 2” gene, also known as “T-cell immunoglobulin and mucin domain-containing protein 3 (TIM3)” gene.
- • TIGIT
- “T-Cell Immunoreceptor With Ig And ITIM Domains” gene.
- • GITR or TNFRSF18
- “Tumour necrosis factor receptor superfamily member 18” gene, also known as “glucocorticoid-induced TNFR-related protein (GITR)” gene.
- • VISTA, C10ORF54 or VSIR
- “V-Set Immunoregulatory Receptor”, also known as “V-Type Immunoglobulin Domain-Containing Suppressor Of T-Cell Activation” gene.
- • PDCD1/LAG3 profile or signature
- we refer as PDCD1/LAG3 in this manuscript as the gene expression profile commonly associated to PDCD1 and LAG3 expression profiles.
- • PD-1/LAG-3 profile or signature
- we refer as PD-1/LAG-3 in this manuscript as the protein expression profile commonly associated to PD-1 and LAG-3 expression profiles.
- • PDCD1 and LAG3 profiles or signatures
- we refer as LAG3 and PDCD1 in this manuscript as the sum of LAG3 gene profile and PDCD1 gene profile separately.
- • PD-1 and LAG-3 profiles or signatures
- we refer as PD-1 and LAG-3 in this manuscript as the sum of PD-1 protein profile and LAG-3 protein profile separately.
- • PD-1+LAG-3
- we refer as PD-1+LAG-3 in this manuscript as the modified T-cell lines co- expressing SC3-PD-1 and SC3-LAG-3 molecules.
- • TCR
- T-cell receptor.
- • TOX
- “Thymocyte selection-associated high mobility group box factor” gene.
